ResearchPod Summary
This study aimed to quantify the global and regional prevalence and health burden of drug use disorders (DUDs)—specifically amphetamine, cannabis, cocaine, and opioid use disorders—across 204 countries and territories from 1990 to 2023. By leveraging data from the Global Burden of Disease Study 2023, the researchers sought to understand longitudinal trends, the impact of cannabis legalization, and how the COVID-19 pandemic influenced these outcomes.
The authors utilized the Global Burden of Disease (GBD) 2023 framework, which synthesizes diverse data sources, including vital registration, surveillance databases, and systematic reviews. They applied diagnostic criteria derived from DSM-IV and ICD-10 to define nonfatal burden, while using cause-specific modeling (CODEm) for fatal outcomes. To handle missing or low-quality data, they utilized redistribution algorithms for garbage codes and Bayesian meta-regression (MR-BRT) for crosswalking between varying data sources. The study assessed the association between DUD burden, socio-demographic indicators (SDI), and regional cannabis legalization status, while also analyzing the impact of the COVID-19 pandemic on prevalence trends.
Global age-standardized disability-adjusted life-years (DALYs) attributable to DUDs rose from 169.3 per 100,000 people in 1990 to 212.0 in 2023. Opioid use disorder (OUD) emerged as the most burdensome, with its prevalence and associated DALYs nearly doubling. High-income countries—particularly the USA, Canada, and Australia—consistently reported higher burdens compared to other regions. Furthermore, countries with more permissive cannabis policies (legal for both recreational and medical use) were associated with significantly higher prevalence and burden of all types of DUDs. While prevalence trends for many disorders were increasing or stable, the rate of increase for CUD and OUD slowed during the COVID-19 pandemic compared to the 2015–2019 period.
The rising trend in DUDs, particularly the opioid crisis, poses a severe challenge to public health systems. The findings highlight significant regional disparities and suggest that social and policy environments, such as cannabis legalization and pharmaceutical regulations, play a critical role in shaping the burden of drug use. The study underscores the necessity for proactive, multi-faceted interventions, including improved addiction treatment access, harm reduction strategies like naloxone distribution, and robust health surveillance, especially in regions currently lacking comprehensive data.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.